Capsule Summary
What is already known
The rate of favorable neurological outcomes after out-of-hospital cardiac arrest remains low. Pheochromocytoma-induced cardiomyopathy is relatively rare, and most cases are incidentally detected on imaging. An implantable cardioverter-defibrillator might be needed for patients with pheochromocytoma-induced cardiomyopathy because structural normalization of the heart after the operation could take a long time.
What is new in the current study
Multidisciplinary treatment, including venoarterial extracorporeal membrane oxygenation and cardioverter-defibrillator implantation, saved a patient with pheochromocytoma-induced cardiomyopathy. Early detection and rapid therapy could enable patients to be discharged without any complications.
A man in his 50s had experienced unintended weight loss and required progressively more intensive antihypertensive therapy over several months before presentation, along with new-onset headaches that developed a few days prior. On the day of presentation, he suddenly collapsed while playing a gambling machine. However, no bystander-initiated cardiopulmonary resuscitation was performed before the arrival of emergency medical services personnel. The first documented on-scene cardiac rhythm was ventricular fibrillation, for which the emergency medical team administered two defibrillation shocks. Return of spontaneous circulation was briefly achieved but not sustained. His refractory ventricular fibrillation required venoarterial extracorporeal membrane oxygenation as a lifesaving intervention. Emergency coronary angiography showed no significant stenosis. A diagnosis of pheochromocytoma-induced cardiomyopathy was suggested based on imaging findings (
Figs. 1,
2). Indeed, the patient’s urinary metanephrine and normetanephrine levels were elevated to more than three times the upper reference limit. Venoarterial extracorporeal membrane oxygenation was successfully weaned on hospital day 3. On hospital day 23, he underwent open right adrenalectomy, and histopathological examination confirmed pheochromocytoma. To prevent recurrence, an implantable cardioverter-defibrillator was implanted on hospital day 35. He was discharged on hospital day 43.
An implantable cardioverter-defibrillator may be required in patients with pheochromocytoma-induced cardiomyopathy because a prolonged period may be needed for structural normalization of the heart after surgery [
1–
4]. A previous study reported that recurrence is more common in younger patients and those with larger tumors [
5]. Although pheochromocytoma-induced cardiomyopathy is relatively rare, most cases are incidentally discovered through imaging findings [
6]. As illustrated in this case, early detection and prompt therapy can enable recovery and discharge without complications.
NOTES
-
Ethics statement
Written informed consent for publication was obtained from the patient’s family.
-
Author contributions
Conceptualization: YS, TH; Investigation: all authors; Project administration: TH; Supervision: HM; Visualization: YS, TH, KW; Writing–original draft: YS, TH; Writing-review & editing: all authors. All authors read and approved the final manuscript.
-
Conflicts of interest
The authors have no conflicts of interest to declare.
-
Funding
The authors received no financial support for this study.
-
Acknowledgments
The authors thank all medical professionals from Dokkyo Medical University Saitama Medical Center for their valuable clinical support in the management of the patient.
-
Data availability
Data sharing is not applicable as no new data were created or analyzed in this study.
Fig. 1.Adrenal mass. (A) Computed tomography reveals a large right adrenal mass (arrow; maximum diameter, approximately 95 mm). The mass shows internal heterogeneity, suggesting either adrenocortical carcinoma or pheochromocytoma. (B) Abdominal magnetic resonance imaging (T2-weighted image) demonstrates a hyperintense lesion (arrow) within the right adrenal gland. (C) 123I-meta-iodobenzylguanidine scintigraphy shows intense radiotracer uptake corresponding to the adrenal mass. These findings strongly indicate the presence of pheochromocytoma.
Fig. 2.Hypertrophy of the ventricular septum. (A) Transthoracic echocardiography reveals ventricular septal hypertrophy (arrow) measuring approximately 19 mm (upper reference limit, 15 mm). (B) Cardiac magnetic resonance imaging (T2-weighted image) shows relatively uniform hypertrophy of the ventricular septum (arrow). These findings strongly suggest the presence of pheochromocytoma-induced cardiomyopathy.
REFERENCES
- 1. Dobrowolski P, Januszewicz A, Klisiewicz A, et al. Left ventricular structural and functional alterations in patients with pheochromocytoma/paraganglioma before and after surgery. JACC Cardiovasc Imaging 2020;13:2498-509.
- 2. Vishvak Chanthar KM, Khanna R, Agarwal G, et al. Cardiac changes and their reversal following curative surgery in pheochromocytoma: PheoCard prospective cohort study. World J Surg 2023;47:304-11.
- 3. Vladimirova-Kitova L, Kitov S, Uchikov P, Pavlov G. Catecholamine-induced cardiomyopathy: a clinical case. Folia Med (Plovdiv) 2022;64:156-61.
- 4. Stenström G, Holmberg S. Cardiomyopathy in phaeochromocytoma: report of a case with a 16-year follow-up after surgery and review of the literature. Eur Heart J 1985;6:539-44.
- 5. Amar L, Servais A, Gimenez-Roqueplo AP, Zinzindohoue F, Chatellier G, Plouin PF. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab 2005;90:2110-6.
- 6. Gruber LM, Hartman RP, Thompson GB, et al. Pheochromocytoma characteristics and behavior differ depending on method of discovery. J Clin Endocrinol Metab 2019;104:1386-93.
Citations
Citations to this article as recorded by
